H.J.P Fokkenrood

Innovative strategies for
intermittent claudication

towards a stepped care approach and new outcome measures

MENU

REFERENCES

PREVIOUSNEXT
  1.  Rapport "De zorg: hoeveel extra is het ons waard? Dutch Ministry of Health Welfare and Sports. 12-06-2012.
  2.  Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. Jan 2007;45 Suppl S:S5-67.
  3.  Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. Aug 10 2004;110(6):738-743.
  4.  Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. Mar 21 2006;113(11):e463-654.
  5.  Lauret GJ, van Dalen DC, Willigendael EM, et al. Supervised exercise therapy for intermittent claudication: current status and future perspectives. Vascular. Feb 2012;20(1):12-19.
  6.  Criqui MH. Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol. Oct 11 2001;88(7B):43J-47J.
  7.  Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. Feb 6 1992;326(6):381-386.
  8.  Dormandy J, Heeck L, Vig S. Predictors of early disease in the lower limbs. Semin Vasc Surg. Jun 1999;12(2):109-117.
  9.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. Jul 6 2002;360(9326):7-22.
  10.  Erb W. About intermittent walking and nerve disturbances due to vascular disease [Uber das "intermitterende Hinken" und adere nervose Storungen in Folge von Gefasserkrankungen] Deutsch Z Nervenheilk. 1898;13:1–76.
  11.  Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008(4):CD000990.
  12.  Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006(2):CD005263.
  13.  Nicolai SP, Teijink JA, Prins MH. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg. Aug 2010;52(2):348-355.
  14.  Bartelink M, Stoffers H, Boutens E, Hooij J, Kaiser V, Boomsma L. NHG-standaard Perifeer arterieel vaatlijden [Guideline peripheral arterial disease from the Dutch General Practioners Society]. Huisarts en Wetenschap 2003;46::848-858.
  15.  Vahl AC. Richtlijn diagnostiek en behandeling van arterieel vaatlijden van de onderste extremiteit2005.
  16.  Lauret GJ, van Dalen HC, Hendriks HJ, et al. When is supervised exercise therapy considered useful in peripheral arterial occlusive disease? A nationwide survey among vascular surgeons. Eur J Vasc Endovasc Surg. Mar 2012;43(3):308-312.
PREVIOUSNEXT